EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells

详细信息    查看全文

• 作者：Chun-Yu Liu^a ; ^b ; ^j ; Tzu-Ting Huang^a ; ^j ; Chun-Teng Huang^b ; ^e ; Ming-Hung Hu^c ; ^d ; Duen-Shian Wang^a ; Wan-Lun Wang^a ; Wen-Chun Tsai^a ; Chia-Han Lee^a ; Ka-Yi Lau^a ; Hsiu-Ping Yang^a ; Ming-Huang Chen^a ; ^b ; Chung-Wai Shiau^f ; Ling-Ming Tseng^b ; ^g ; ^j ; ^{lmtseng@vghtpe.gov.tw} ; Kuen-Feng Chen^h ; ⁱ ; ^{kfchen1970@ntu.edu.tw}
• 关键词：Elk1 ; CIP2A ; Erlotinib ; EGFR ; Triple-negative breast cancer
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：72
• 期：Complete
• 页码：112-123
• 全文大小：2525 K
• 卷排序：72

文摘

TD52 enhances cell apoptosis in triple-negative breast cancer (TNBC) cells in vitro and in vivo. TD52 induces TNBC cell apoptosis via Elk1/CIP2A/p-Akt pathway. High Elk1 expression is associated with worse relapse-free survival in patients with TNBC.